A Phase 1/2 interventional study of Selinexor 100 mg and Docetaxel in Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) and Other Solid Tumors, sponsored by Karyopharm Therapeutics Inc. Completed at 11 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Karyopharm Therapeutics Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel — 47 open to participants now, 95 under way, 44 of them phase 3. Carcinoma, Non-Small-Cell Lung · Israel.
Among the 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel, this one is the 167th largest by enrollment of the 206 interventional ones that give a count, is one of 20 that started in 2020, is one of 20 in phase 1/2, and was the 127th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →47 of the 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel are open now. Recruiting first, the newest first:
Pfizer · Sites in Israel, United States, Australia and 8 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Israel, United States, Australia and 17 more countries
Ages 18+
Boehringer Ingelheim · Sites in Israel, United States, Argentina and 25 more countries
Ages 18+
Pfizer · Sites in Israel, United States, Argentina and 17 more countries
Ages 18+
AbbVie · Sites in Israel, United States, Australia and 17 more countries
Ages 18+
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 74 · Phase 3 103 · Phase 4 3
First in 1995; this study’s year is marked. 20 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 329 across the 206 interventional studies, 340 across the 14 observational. Of the 114 that completed or were terminated, 71 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 222 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
21 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Israel that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
| NCT06074588Phase 3Merck Sharp & Dohme LLCSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | 2027-05-10 |
| NCT05973773Phase 3Taiho Oncology, Inc.REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) | 2027-05-27 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
Add all 21 to your calendar (.ics) → With an account.
Among the 222 studies in Carcinoma, Non-Small-Cell Lung with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a checkpoint Inhibitor (CPI); or patients with normal HF, with colorectal cancer (CRC) who have had 1-3 prior lines (KRAS wild-type [WT]) or 1-2 prior lines (mutant KRAS) of treatment with no CPI; or patients with impaired HF, with any solid tumor, who have had at least 1 prior line of treatment.
The study will comprise 2 treatment periods (monotherapy and combination therapy).
The purposes of this study, during Monotherapy period, are: (1) to determine the relative bioavailability of the 100 milligrams (mg) (Tablet B) and 20 mg (Tablet A) tablets of selinexor at 100 mg once weekly (QW) dose in patients with normal hepatic function; and (2) to assess the PK of selinexor after a single dose of 40 mg (2 × 20 mg), among patients with moderate and severe hepatic impairment, relative to 100 mg (5 × 20 mg), among patients with normal hepatic function; and, during the Combination therapy period, to assess the preliminary anti-tumor activity of selinexor in combination with docetaxel in patients with NSCLC and with pembrolizumab or folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) in patients with CRC.
Up to 120 patients will be enrolled, of which, 20 with normal HF will be able to continue from Monotherapy to Combination therapy and up to 106 patients with normal HF will receive combination therapy in total. Patients with impaired hepatic function can only participate in the Monotherapy part of the study.
Monotherapy Period:
For the Monotherapy Period of Study KCP-330-027, patients with normal hepatic function (n=20), will be allocated to one of two test formulation treatment arms, and will receive a cross-over once weekly oral dosing, with either 1x100 mg or 5x20 mg selinexor, for 2 weeks, and then will have the option to move on to the combination treatment part of the study. Patients with either moderately or severely impaired hepatic functions will be treated with 2x20 mg selinexor weekly (with an option to increase the dose every 3 weeks by 20 mg increments, up to 80 mg).
For the assessment of hepatic impairment, participants with any type of advanced or metastatic solid tumor who have moderate or severe hepatic impairment will be enrolled in Moderate Hepatic Impairment (MHI) (n=8) and Severe Hepatic Impairment (SHI) (n=6) arms, respectively and will be treated with 2 × 20 mg selinexor, weekly.
For Weeks 1 and 2, following an overnight fast of at least 10 hours, patients will be fed a standard low-fat meal 30 minutes prior to administration of once weekly selinexor. Patients should finish the meal in 30 minutes or less; however, selinexor dose should be administered 30 minutes after start of the meal.
Blood sampling for selinexor PK analyses will be collected ≤10 minutes (m) pre selinexor dose, and at 15m (±5m), 30m (±5m), 1 hour (h) (±5m), 1.5h (±5m), 2h (±10m), 3h (±10m), 4h (±10m), 5h (±10m), 6h (±10m), 8h (±20m), 10h (±20m; optional), 24h (±1h), 30h (±1h), and 48h (±2h) post selinexor dose. Practitioners must record the actual clock time for selinexor dose, and each sample drawn.
If a patient experiences emesis during the first 6 hours of the PK sampling, the PK results for that week will be excluded from the PK analysis dataset, and all testing timepoints must be re-collected during the following week (in this case, the same dosing formulation should be repeated on the following week, and other dosing formulation will be given the week after that).
Patients who will complete the Monotherapy Period will be reassessed for continuation to the Combination Therapy Period, as long as their Hepatic Function remains normal.
If a patient experiences significant toxicity related to selinexor and can't start the combination therapy immediately following monotherapy, dose interruption and weekly retesting are allowed for up to 21 days after the end of Monotherapy treatment visit. Patients requiring >21 days to recover from toxicities related to selinexor should be discussed with the Sponsor's Medical Monitor for documented approval to continue to the Combination Therapy Period. Reassessment may be extended then and following Medical Monitor approval up to 28 days.
Combination Therapy Period:
In the combination treatment period of the study, patients with normal hepatic functions will be allocated to one of 3 arms (with Arm C divided into 2 cohorts): Arm A (n= up to 40): Patients with NSCLC who have had up to 2 lines of prior systemic treatment with 1 line containing a CPI will receive 60 mg selinexor weekly, in combination with docetaxel 75 milligrams per meter square (mg/m\^2) once every 3 weeks; Arm B (n= up to 40): Patients with CRC (KRAS WT) who have had up to 3 lines of prior systemic treatment or patients with CRC (KRAS mutant [KRAS Mut]) who have had up to 2 lines of prior systemic treatment, with no lines containing a checkpoint inhibitor (CPI) will receive 80 mg selinexor weekly, in combination with pembrolizumab 200 mg once every 3 weeks; Arm C (n\<=26): Patients with CRC (regardless of KRAS status) who have had up to 2 lines of prior systemic treatment (regardless of CPI use) will receive either: (Cohort 1) selinexor 40 mg on days 1, 3, 15 and 18 in 28-day cycle + FOLFIRI; or (Cohort 2) selinexor 80 mg on days 1 and 15 in 28-day cycle + FOLFIRI.
Combination Therapy Period Patients will receive combination treatment until progressive disease (PD) or intolerable toxicity.
During both study periods, safety will be assessed through continuous reporting of adverse events (AEs), treatment-emergent adverse events (TEAEs), regularly scheduled clinical laboratory tests (hematologic and chemical), and physical examinations.
Tumor assessment will be performed with either computed tomography (CT) or magnetic resonance imaging (MRI) (CT with contrast preferred; for each patient, the imaging method should remain the same throughout the study).
Following treatment, patients will come in for a safety visit (approximately 30 days after the last dose of combination therapy) and will be followed for up to 2 years after that. Patients who discontinued due to PD will be followed for survival, and patients who discontinued for reasons other than PD will have tumor assessments until PD or until the start of new anti-neoplastic therapy, after which they will be followed for survival.
The criteria were revised on the registry on Oct 9, 2026. See what changed
Key Inclusion Criteria:
Common inclusion criteria for all patients:
Female patients of must have a negative serum pregnancy test at screening and agree to use highly effective (dual methods of) throughout the study and for 4 months following the last dose of study drug (childbearing potential excludes: Age >50 years and naturally amenorrhoeic for >1 year, or previous bilateral salpingo-oophorectomy or hysterectomy); and male patients must use an effective barrier method of contraception throughout the study and for 4 months following the last dose of study drug if sexually active. Male patients must agree not to donate sperm during the study treatment period.
For the Monotherapy Part only (bioavailability/bioequivalence [BA/BE] and hepatic impairment [HI] arms):
Must have either normal hepatic function, or moderate or severe hepatic impairment (as defined by the NCI organ dysfunction working group (NCI-ODWG) criteria:
S20-100 and S100-20 arms: normal hepatic function (total and [AST] less than or equal to [≤] [ULN]).
Note: Patients with mild hepatic dysfunction (total bilirubin greater than [>] 1 to 1.5 × ULN or AST > ULN) may be included if liver function tests are stable for the past 3 months and enrollment is approved in writing by the Sponsor's Medical Monitor.
For Combination Therapy Part only:
Previous treatment lines (adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy):
Arm B: For patients with RAS mutant CRC, 1-2 prior lines of systemic treatments, and no prior anti- programmed cell death protein 1/L1 monoclonal antibody (anti-PD-1/L1 mAb).
Must have hepatic function as follows:
Key Exclusion Criteria:
Common exclusion criteria for all patients:
Have inadequate hematopoietic function defined as (without transfusion or growth factor support within 7 days prior to first dose):
Ongoing infection requiring parenteral antibiotics, antivirals, or antifungals on Day 1 dosing.
a. All patients: on Day 1 dosing.
Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:
Female patients who are pregnant or breastfeeding.
For Monotherapy Part only (BA/BE and HI arms):
Have an (ECOG) performance status of:
Inability or unwillingness to undergo a series of PK sampling.
For Combination Therapy Part only:
Arm B patients with CRC who are to receive pembrolizumab:
Have active disease requiring systemic treatment during the past 2 years. Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted.
Note: The Investigator needs to evaluate the patient's medical history to confirm that they are eligible to receive the combination with pembrolizumab per these criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Closed for Enrollment) S20-100 arm: * Week 1: selinexor 5 x 20-mg tablet once weekly (QW). * Week 2: selinexor 1 x 100-mg tablet QW. S100-20 arm: * Week 1: selinexor 1 x 100-mg tablet QW. * Week 2: selinexor 5 x 20-mg tablet QW.
Drug: Selinexor 100 mg
Cohort 1: Patients with Moderate Hepatic Impairment with any Solid Tumors. - Selinexor 2 x 20-mg tablet QW. Cohort 2: Patients with Severe Hepatic Impairment with any Solid Tumors. \- Selinexor 2 x 20-mg tablet QW.
Drug: Selinexor 40 mg
(Closed for Enrollment) Selinexor 60 mg oral dose QW and docetaxel 75 mg/m\^2 intravenously (IV) once every 3 weeks (non-small cell lung cancer \[NSCLC\] patients).
Drug: Docetaxel · Drug: Selinexor 60 mg
(Closed for Enrollment) Selinexor 80 mg oral dose QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer \[CRC\] Patients).
Drug: Pembrolizumab · Drug: Selinexor 80 mg
(Closed for Enrollment) Cohort 1: Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5- fluorouracil (5-FU) 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients). Cohort 2: Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m\^2; leucovorin 400 mg/m\^2; 5-FU 400 mg/m\^2 bolus then 5-FU 2400 mg/m\^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).
Drug: FOLFIRI · Drug: Selinexor 40 mg · Drug: Selinexor 80 mg
100-mg 2 formulations: * 5 × 20-mg tablets (Tablet A) * 1 × 100-mg tablet (Tablet B)
Also known as: Xpovio®
75 mg/m\^2 IV
Also known as: Taxotere®
200 mg IV
Also known as: Keytruda®
FOLFIRI: * Irinotecan 180 mg/m\^2 * Leucovorin 400 mg/m\^2 * 5-FU 400 mg/m\^2 bolus * 5-FU 2400 mg/m\^2 IV
\- 2 × 20-mg tablets (Tablet A)
Also known as: Xpovio®
\- 4 × 20-mg tablets (Tablet A)
Also known as: Xpovio®
\- 3× 20-mg tablets (Tablet A)
Also known as: Xpovio®
Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
AUC0-t was defined as the total-drug area under the concentration-time curve from time zero to time of last concentration measured.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), calculated as AUC0-last + Ct/λ, where: Ct = the last quantifiable concentration and λ is terminal elimination rate constant.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
Cmax was defined as maximum observed plasma total-drug concentration of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Overall response rate (ORR) was defined as the percentage of participants who achieved an Investigator-determined best overall response (BOR) of partial response (PR) or complete response (CR) as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants who achieved ORR were reported.
Time frame: Up to 25 months
Combination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Adverse event (AE): Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
Time frame: From start of study drug administration up to survival follow-up (up to 25 months)
Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
Tmax was defined as time to the maximum observed concentration of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
Lambda z was defined as the terminal elimination rate constant of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
t1/2 was defined as the terminal elimination half-life of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
CL/F was defined as the apparent clearance of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment
Vd/f was defined as the apparent volume of distribution, calculated as Dose/ (λz\*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein
Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. Mean percent fraction unbound of selinexor (Tablet A) in plasma, calculated by averaging the percent fraction unbound measurements obtained at 3 and 8 hours post-dose on Days 1 and 8.
Time frame: At 3 and 8 hours post-dose on Days 1 and 8
Monotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma
Cmax,u was defined as the maximum observed free-drug concentration of Selinexor, calculated as Cmax \* Fu.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma
AUCu was defined as free-drug area under the concentration-time curve from time zero to infinity (extrapolated), calculated as (AUC0-last + Ct/λz) \* Fu, where: Ct = the last observed nonzero concentration.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma
CLu/F was defined as the apparent free-drug clearance of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Monotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma
Vu/F was defined as the apparent free-drug volume of distribution of selinexor.
Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8
Combination Therapy (Arms: A, B and C): Progression-free Survival (PFS)
PFS was defined as the time from the starting date of the combination therapy until the date of first progressive disease (PD) determined by PI per Response Evaluation Criteria in Solid Tumors (RECIST) for Arm A and B or Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST) for Arm C, or death due to any cause, whichever occurred first.
Time frame: Time from starting date of combination therapy until the date of first PD or death due to any case, whichever occurs first (up to 25 months)
Combination Therapy (Arms: A, B and C): Duration of Response (DOR)
DOR was defined for participants with partial response (PR) or complete response (CR) as the duration from the date of first PR or better to the date of first PD or death due to any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Date of first PR or better to the date of first PD or death due to any cause, whichever occurs first (up to 25 months)
Combination Therapy (Arms: A, B and C): Disease Control Rate (DCR)
DCR was calculated as the percentage of participants for whom the best overall response (BOR) was determined as CR, PR, or at least 12 continuous weeks of stable disease as assessed by RECIST v1.1 (Arms A, C), and iRECIST (Arm B), before Investigator had determined PD or initiating a new antineoplastic therapy. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 25 months
Combination Therapy (Arms: A, B and C): Overall Survival (OS)
OS was defined as time since the starting date of the combination therapy until death due to any cause.
Time frame: Time since the starting date of combination therapy until death due to any cause (up to 25 months)
Monotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
AE Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
Time frame: From start of study drug administration up to survival follow-up (up to 4 months)
Combination Therapy (Arms: A and B): Number of Participants With TEAEs
AE: Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
Time frame: From start of study drug administration up to survival follow-up (up to 25 months)
Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1
ORR was defined as the proportion of participants who achieve an Investigator-determined BOR of PR or CR as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 25 months
A total of 80 participants were enrolled. Of these, 79 participants received treatment (35 received monotherapy, and 44 received combination therapy). After completing 4 months of monotherapy treatment, participants from the normal hepatic function arm were transitioned to the combination therapy (4 into NSCLC Arm A and 15 into CRC Arm B) to continue the treatment, as planned in the protocol.
| Milestone | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|---|---|---|---|
| Started | 11 | 11 | 7 | 6 | 0 | 0 | 0 | 0 |
| Participants treated during monotherapy | 11 | 11 | 7 | 6 | 0 | 0 | 0 | 0 |
| Completed | 10 | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 2 | 7 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical progression | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Not eligible for combination therapy | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 17 | 38 | 6 | 2 |
| Unique participants in combination therapy | 0 | 0 | 0 | 0 | 13 | 23 | 6 | 2 |
| Participants from monotherapy: normal hepatic function (tablet a first, then tablet b) | 0 | 0 | 0 | 0 | 2 | 8 | 0 | 0 |
| Participants from monotherapy: normal hepatic function (tablet b first, then tablet a) | 0 | 0 | 0 | 0 | 2 | 7 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 17 | 38 | 6 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 0 | 4 | 7 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 5 | 21 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 4 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
AUC0-t was defined as the total-drug area under the concentration-time curve from time zero to time of last concentration measured.
| hour*nanograms per milliliter (h*ng/mL) | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Area Under the Concentration-Time Curve From Time Zero to Time of Last Concentration (AUC 0-t) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 6830 ± 28.8 | 6920 ± 27.2 | 2380 ± 24.0 | 3860 ± 22.4 |
AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated), calculated as AUC0-last + Ct/λ, where: Ct = the last quantifiable concentration and λ is terminal elimination rate constant.
| h*ng/mL | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-Inf) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 6880 ± 28.7 | 6980 ± 27.1 | 2270 ± 16.3 | 4060 ± 24.4 |
Cmax was defined as maximum observed plasma total-drug concentration of selinexor.
| nanograms per milliliter (ng/mL) | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Maximum Plasma Concentration (Cmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 782 ± 40.8 | 813 ± 25.6 | 272 ± 36.4 | 372 ± 42.1 |
Overall response rate (ORR) was defined as the percentage of participants who achieved an Investigator-determined best overall response (BOR) of partial response (PR) or complete response (CR) as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants who achieved ORR were reported.
| Percentage of participants | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab |
|---|---|---|
| Combination Therapy (Arms: A and B): Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 11.8 (1.5 to 36.4) | 0 (0 to 0) |
Adverse event (AE): Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
| Participants | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|
| Combination Therapy (Arm C): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 6 | 2 |
Tmax was defined as time to the maximum observed concentration of selinexor.
| hours | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Time to Maximum Observed Concentration (Tmax) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 4.00 (1.58 to 9.92) | 2.92 (0.25 to 5.83) | 5.93 (1.45 to 10.00) | 5.08 (3.08 to 7.75) |
Lambda z was defined as the terminal elimination rate constant of selinexor.
| liter per hour (l/h) | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Terminal Elimination Rate Constant (Lambda z) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 0.101 ± 19.3 | 0.106 ± 28.6 | 0.124 ± 29.8 | 0.128 ± 50.3 |
t1/2 was defined as the terminal elimination half-life of selinexor.
| hour | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Terminal Half-Life (t1/2) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 6.88 ± 19.3 | 6.57 ± 28.6 | 5.57 ± 29.8 | 5.43 ± 50.3 |
CL/F was defined as the apparent clearance of selinexor.
| L/h | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Apparent Clearance (CL/F) of Total Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 14.5 ± 28.7 | 14.3 ± 27.1 | 17.6 ± 16.3 | 9.86 ± 24.4 |
Vd/f was defined as the apparent volume of distribution, calculated as Dose/ (λz\*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight.
| liter | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 X 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment | 144 ± 39.2 | 136 ± 45.0 | 142 ± 41.5 | 77.2 ± 24.2 |
Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. Mean percent fraction unbound of selinexor (Tablet A) in plasma, calculated by averaging the percent fraction unbound measurements obtained at 3 and 8 hours post-dose on Days 1 and 8.
| Percent unbound | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|
| Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein | 4.19 ± 0.918 | 5.33 ± 1.11 | 4.4 ± 0.505 |
Cmax,u was defined as the maximum observed free-drug concentration of Selinexor, calculated as Cmax \* Fu.
| ng/mL | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|
| Monotherapy: Maximum Free-Drug Concentration (Cmax,u) of Free Selinexor (Tablet A) in Plasma | 34.5 ± 46.5 | 14.2 ± 38.6 | 16.3 ± 51.8 |
AUCu was defined as free-drug area under the concentration-time curve from time zero to infinity (extrapolated), calculated as (AUC0-last + Ct/λz) \* Fu, where: Ct = the last observed nonzero concentration.
| h*ng/mL | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|
| Monotherapy: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Free Selinexor (Tablet A) in Plasma | 297 ± 39.6 | 113 ± 18.7 | 184 ± 29.5 |
CLu/F was defined as the apparent free-drug clearance of selinexor.
| L/h | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|
| Monotherapy: Apparent Free-drug Clearance (CLu/F) of Free Selinexor (Tablet A) in Plasma | 336 ± 39.6 | 353 ± 18.7 | 217 ± 29.5 |
Vu/F was defined as the apparent free-drug volume of distribution of selinexor.
| liter | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 X 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|
| Monotherapy: Apparent Free-drug Volume of Distribution (Vu/F) of Free Selinexor (Tablet A) in Plasma | 3170 ± 37.9 | 2840 ± 36.6 | 1700 ± 22.2 |
PFS was defined as the time from the starting date of the combination therapy until the date of first progressive disease (PD) determined by PI per Response Evaluation Criteria in Solid Tumors (RECIST) for Arm A and B or Immunotherapeutic Response Evaluation Criteria in Solid Tumors (iRECIST) for Arm C, or death due to any cause, whichever occurred first.
| months | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|
| Combination Therapy (Arms: A, B and C): Progression-free Survival (PFS) | 5.78 (3.15 to NA) | 1.97 (1.91 to 3.94) | 1.86 (1.54 to NA) | 2.76 (1.71 to NA) |
DOR was defined for participants with partial response (PR) or complete response (CR) as the duration from the date of first PR or better to the date of first PD or death due to any cause, whichever occurred first. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| months | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|
| Combination Therapy (Arms: A, B and C): Duration of Response (DOR) | 14.49 (NA to NA) | — | — | — |
DCR was calculated as the percentage of participants for whom the best overall response (BOR) was determined as CR, PR, or at least 12 continuous weeks of stable disease as assessed by RECIST v1.1 (Arms A, C), and iRECIST (Arm B), before Investigator had determined PD or initiating a new antineoplastic therapy. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|
| Combination Therapy (Arms: A, B and C): Disease Control Rate (DCR) | 58.8 (32.9 to 81.6) | 28.9 (15.4 to 45.9) | 0 (0 to 0) | 50 (1.3 to 98.7) |
OS was defined as time since the starting date of the combination therapy until death due to any cause.
| months | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|
| Combination Therapy (Arms: A, B and C): Overall Survival (OS) | 6.01 (5.49 to NA) | 8.25 (7.03 to 11.70) | 4.76 (4.14 to NA) | 6.83 (5.06 to NA) |
AE Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
| Participants | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet): Moderate Hepatic Function | Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function |
|---|---|---|---|---|
| Monotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 9 | 11 | 7 | 4 |
AE: Any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs were any event that was not present prior to the initiation of study treatment, or any event already present that worsened in either intensity or frequency following exposure to study treatment.
| Participants | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab |
|---|---|---|
| Combination Therapy (Arms: A and B): Number of Participants With TEAEs | 17 | 37 |
ORR was defined as the proportion of participants who achieve an Investigator-determined BOR of PR or CR as assessed by RECIST or iRECIST before disease progression or initiating a new antineoplastic treatment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) might have reduction in the short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|
| Combination Therapy (Arm C): Percentage of Participants With ORR as Assessed by RECIST 1.1 | 0 (0 to 0) | 0 (0 to 0) |
Collected over Monotherapy: From start of study drug administration (Day 1) up to survival follow-up (up to 4 months); Combination therapy: From start of study drug administration (Day 1) up to survival follow-up (up to 25 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | 1/11 (9.1%) | 4/11 (36.4%) | 9/11 (81.8%) |
| Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | 1/11 (9.1%) | 1/11 (9.1%) | 11/11 (100%) |
| Monotherapy: Moderate Hepatic Function (Tablet A Only) | 3/7 (42.9%) | 5/7 (71.4%) | 7/7 (100%) |
| Monotherapy: Severe Hepatic Function (Tablet A Only) | 5/6 (83.3%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | 11/17 (64.7%) | 11/17 (64.7%) | 17/17 (100%) |
| Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | 30/38 (78.9%) | 10/38 (26.3%) | 37/38 (97.4%) |
| Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) | 2/2 (100%) | 1/2 (50%) | 2/2 (100%) |
| Event | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|---|---|---|---|
| Deep vein thrombosisVascular disorders | 0/11 | 0/11 | 0/7 | 0/6 | 0/17 | 0/38 | 0/6 | 1/2 |
| PyrexiaGeneral disorders | 1/11 | 0/11 | 0/7 | 0/6 | 0/17 | 0/38 | 2/6 | 0/2 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/11 | 0/11 | 0/7 | 1/6 | 0/17 | 0/38 | 0/6 | 0/2 |
| Respiratory tract infection viralInfections and infestations | 0/11 | 0/11 | 0/7 | 1/6 | 0/17 | 0/38 | 0/6 | 0/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/11 | 0/11 | 0/7 | 0/6 | 2/17 | 0/38 | 1/6 | 0/2 |
| HypotensionVascular disorders | 0/11 | 0/11 | 0/7 | 0/6 | 0/17 | 0/38 | 1/6 | 0/2 |
| CholangitisHepatobiliary disorders | 0/11 | 0/11 | 1/7 | 0/6 | 0/17 | 0/38 | 0/6 | 0/2 |
| CholecystitisHepatobiliary disorders | 0/11 | 0/11 | 1/7 | 0/6 | 0/17 | 0/38 | 0/6 | 0/2 |
| Device related infectionInfections and infestations | 0/11 | 0/11 | 1/7 | 0/6 | 0/17 | 0/38 | 0/6 | 0/2 |
| SepsisInfections and infestations | 0/11 | 0/11 | 1/7 | 0/6 | 0/17 | 1/38 | 0/6 | 0/2 |
| Event | Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function | Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) |
|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 3/11 | 8/11 | 1/7 | 1/6 | 4/17 | 11/38 | 1/6 | 1/2 |
| NauseaGastrointestinal disorders | 6/11 | 7/11 | 3/7 | 2/6 | 8/17 | 21/38 | 4/6 | 1/2 |
| AnaemiaBlood and lymphatic system disorders | 2/11 | 1/11 | 3/7 | 0/6 | 9/17 | 7/38 | 1/6 | 0/2 |
| Decreased appetiteMetabolism and nutrition disorders | 2/11 | 3/11 | 3/7 | 1/6 | 9/17 | 17/38 | 3/6 | 1/2 |
| LeukocytosisBlood and lymphatic system disorders | 0/11 | 0/11 | 0/7 | 0/6 | 0/17 | 0/38 | 0/6 | 1/2 |
| NeutrophiliaBlood and lymphatic system disorders | 0/11 | 0/11 | 0/7 | 0/6 | 0/17 | 0/38 | 0/6 | 1/2 |
| Abdominal painGastrointestinal disorders | 0/11 | 0/11 | 3/7 | 0/6 | 1/17 | 4/38 | 2/6 | 1/2 |
| AscitesGastrointestinal disorders | 0/11 | 0/11 | 0/7 | 0/6 | 0/17 | 1/38 | 1/6 | 1/2 |
| DyspepsiaGastrointestinal disorders | 0/11 | 1/11 | 0/7 | 0/6 | 2/17 | 0/38 | 0/6 | 1/2 |
| FatigueGeneral disorders | 1/11 | 1/11 | 2/7 | 0/6 | 7/17 | 17/38 | 3/6 | 0/2 |
Baseline characteristics were summarized for all unique enrolled participants who received monotherapy and combination therapy.
| Age, Customized(Participants) | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|
| 18 - 50 | 4 | 3 | 1 | 4 | 0 | 4 | 2 | 1 | 19 |
| 51 - 64 | 1 | 5 | 4 | 2 | 2 | 13 | 4 | 1 | 32 |
| 65 - 74 | 4 | 1 | 2 | 0 | 8 | 5 | 0 | 0 | 20 |
| ≥75 | 2 | 2 | 0 | 0 | 3 | 1 | 0 | 0 | 8 |
| Sex: Female, Male(Participants) | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 5 | 1 | 3 | 4 | 13 | 2 | 0 | 31 |
| Male | 8 | 6 | 6 | 3 | 9 | 10 | 4 | 2 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 11 | 7 | 6 | 13 | 23 | 6 | 2 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Monotherapy: Normal Hepatic Function (Tablet A First, Then Tablet B) | Monotherapy: Normal Hepatic Function (Tablet B First, Then Tablet A) | Monotherapy: Moderate Hepatic Function (Tablet A Only) | Monotherapy: Severe Hepatic Function (Tablet A Only) | Combination Therapy: NSCLC Arm A: Selinexor + Docetaxel | Combination Therapy: CRC Arm B: Selinexor + Pembrolizumab | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 1) | Combination Therapy: CRC Arm C: Selinexor + FOLFIRI (Cohort 2) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| White | 11 | 11 | 7 | 6 | 13 | 22 | 6 | 2 | 78 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2020 to primary completion in Jul 2024, 53 months.
Results were first posted in Oct 2026, 2 years 2 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 53 months is close to that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
Start moved once since we started tracking on Sep 25, 2026: Jan 2020 → Feb 2020, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor
Carcinoma, Non-Small-Cell Lung →